Skip to content

Current Debt at other companies

Eli Lilly logo
Eli LillyLLY
$4B-0.4%
Pfizer logo
PfizerPFE
$3.86B+3.0%
Cytokinetics logo
CytokineticsCYTK
$44.81M+246%
Eton Pharmaceuticals, Inc. logo
Eton Pharmaceuticals, Inc.ETON
$11.81M
Opko Health logo
Opko HealthOPK
$1.53M+7.2%
Aurinia Pharmaceuticals logo
Aurinia PharmaceuticalsAUPH
$16.52M+13.9%

Other financials

Income statement

See full
Revenue$21.1M+1,572%
Gross profit$21.0M+1,604%
Operating income-$996.0K+96.1%
Net income-$1.0M+95.9%
EPS (diluted)$0.00+100%

Balance sheet

See full
Cash & equivalents$67.1M+6.7%
Total debt$57.7M-45.7%
Total equity$202.9M+64.9%
Total assets$268.8M-9.7%

Cash flow

See full
Operating cash flow-$14.7M+66.4%
CapEx--100%
Free cash flow-$17.2M+21.5%

Valuation

See full
Market cap$986.12M+262%
Enterprise value$976.73M+209%
P/S14.2×+5.4×

Profitability

See full
Gross margin99.5%+1.5pp
Operating margin-34.8%-16.8pp
Net margin-37.5%-18.1pp
FCF margin-578.5%-283pp

Returns & leverage

See full
Return on equity-16%-7.2pp
Debt / equity0.3×-0.6×
Current ratio18.8×+16.6×

Where this comes from

Reported directly by Lexicon Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:LongTermDebtCurrent.

The official record: Lexicon Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Lexicon Pharmaceuticals's current debt.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Lexicon Pharmaceuticals's current debt?
Lexicon Pharmaceuticals (LXRX) reported current debt of $0 in Q1 2026.
How has Lexicon Pharmaceuticals's current debt changed year-over-year?
Lexicon Pharmaceuticals's current debt decreased by 100.0% year-over-year, from $42.06M to $0.
What is the long-term trend for Lexicon Pharmaceuticals's current debt?
Over 3 years (2020 to 2025), Lexicon Pharmaceuticals's current debt has grown at a -26.7% compound annual growth rate (CAGR), from $11.65M to $4.6M.
What does current debt mean?
The portion of long-term debt maturing within the next 12 months, requiring refinancing or repayment from operating cash flows.